Groundbreaking and novel assays to help assess organ and tissue damage in transplant patients and COVID-19 – COVID-19
Image: Breakthrough technologies will assess organ and tissue damage in transplant and COVID-19 patients (Photo courtesy of Pexels)
New collaboration will expand access to blood and urine-based cell-free DNA detection methods that will provide healthcare professionals with highly accurate, non-invasive tools to identify and monitor infection, rejection and severity organ damage during transplantation and COVID-19 patients.
Eurofins Viracor, LLC (Lees Summit, MO, USA) has entered into an exclusive licensing agreement with Cornell University (Ithaca, NY, USA) to commercialize several innovative and breakthrough tests aimed at transforming the clinical management of COVID-19 and transplantation patients affected by tissue damage and infections. Surgical biopsy is essential for tracking the damage of COVID-19 in the body, but the procedure can be painful and expensive for the patient. Cornell researchers have developed an alternative to biopsy – a new, non-invasive blood test to measure organ damage caused by COVID-19. The test uses circulating cell-free DNA (cfDNA) to assess the damage that COVID-19 inflicts on cells, tissues and organs.
Additionally, cfDNA is a very versatile analyte for monitoring the most critical complications of hematopoietic cell transplantation (HCT) for many blood disorders and cancers, including graft versus host disease, infection, graft failure and disease relapse. The agreement between Eurofins and Cornell will expand access to an innovative blood-based cDNA methylation sequencing test for the early detection or prediction of major complications related to allogeneic HCT, thereby improving the management of stem cell transplant patients. In another application, Eurofins intends to commercialize the new cfDNA test used to identify the presence of urinary tract infections in kidney transplant patients and quantify the degree of kidney and bladder damage.
Eurofins Viracor, LLC